Executive Summary
To date, Stablepharma has identified over 60 existing vaccines poised for transformation into fridge-free formulations. However, Stablepharma has faced significant financial pressures due to the substantial development costs associated with their innovative adaptable fridge-free technology, alongside the challenges of navigating the intricate R&D tax relief application process.
To address these challenges, FI Group collaborated with Stablepharma. This partnership enabled Stablepharma to maximise their R&D tax claim and secure substantial tax relief, funding the development of additional key candidate vaccines and advancing the market authorisation of the StablevaX™-Td vaccine. In doing so, they optimised their financial resources and reinforced their commitment to revolutionising vaccine accessibility.
About the Stablepharma
- Client Name: Stablepharma Limited
- Industry: Biotechnology Research
- Location: Bath, England
- Company Size: 11-50 employees
Client Overview: Stablepharma is a UK-based biopharmaceutical company committed to developing a range of next-generation fridge-free vaccine products. The Company was founded with a straightforward yet impactful mission: to leverage its innovative technology to significantly improve health outcomes for adults and children who are most vulnerable to death and disability from vaccine-preventable diseases. One of Stablepharma’s key innovations is StablevaX, an adaptable fridge-free technology that extends the shelf life of vaccines, reduces wastage and minimises the carbon footprint associated with the cold-chain distribution and storage of vaccines. According to the World Health Organization (WHO), approximately 50% of all vaccines manufactured are wasted due to failures in the global cold chain. Stablepharma is dedicated to ensuring that all vaccines can be safely removed from the refrigerated cold chain and stored at room temperature for months or even years.
A Challenge for Stablepharma
As a biopharmaceutical company, Stablepharma stands to gain significantly from pursuing R&D tax credits, particularly given the substantial costs involved in developing a pipeline of fridge-free vaccines and pharmaceutical products. By claiming these tax credits, Stablepharma can alleviate some of the financial pressures associated with their research activities, thereby improving cash flow and enabling further investment in innovative research. This financial support would enhance the Company’s capacity to expand their portfolio and focus on developing additional key candidate vaccines that are fridge-free. Ultimately, leveraging these tax credits would advance their mission to eliminate the need for cold-chain logistics, improve global access to vaccines, reduce waste and carbon emissions, and facilitate strategic stockpiling in areas where it is most needed.
However, navigating the ever-changing landscape of R&D tax guidelines can be quite challenging. Recent changes in tax relief regulations have complicated the application process for R&D tax credits. Key adjustments include revised credit rates for the SME and RDEC schemes, the introduction of R&D intensity conditions for loss-making SMEs, and an expansion of qualifying expenditures. Additionally, the requirement for pre-notification to HMRC and the mandatory submission of an Additional Information Form (AIF) have further increased the complexity of the claims process, making it essential for companies to thoroughly understand and meet these new criteria.
These changes make it increasingly challenging for Stablepharma to fully understand how to apply for the relief to which they are entitled and how to maximise the available tax benefits.
Stablepharma’s Solution
At FI Group, a leading specialist in R&D tax credits, we bring a wealth of knowledge and experience to the table. Our unparalleled financial and technical expertise positions us perfectly to assist Stablepharma in identifying eligible projects and maximising their claims for the relief they rightfully deserve. By offering bespoke guidance on documentation and compliance, we have not only streamlined the application process but also significantly reduced the risk of errors or delays. This proactive approach empowers Stablepharma to fully capitalise on the available relief, enabling them to advance their critical research activities.
Our dedicated team at FI Group UK engaged closely with the competent professionals at Stablepharma, meticulously collecting detailed information on projects undertaken during the claim period. We crafted compelling technical narratives that showcased the innovative aspects of Stablepharma’s work while also requesting essential financial statements to ensure a thorough understanding of expenditures.
The Results and Benefits
FI Group played a crucial role in supporting Stablepharma with their R&D tax relief claim under the SME scheme, expertly managing the complexities of the application process. With their extensive knowledge and experience, FI Group identified all eligible projects and efficiently maximised the Company’s claim.
Client Testimonial: ‘We are extremely pleased with the R&D tax work carried out by FI Group during 2024. Giuseppe and his team were great collaborators and quickly assimilated the necessary data to best showcase our R&D efforts, with excellent attention to detail. This resulted in a much-improved claim for our organisation, which will have an immediate impact on the work we can carry out in 2025. We would highly recommend them to other industry colleagues.’
Conclusion
The partnership between Stablepharma and FI Group has been instrumental in navigating the complexities of the R&D tax relief application process. By securing substantial tax relief, Stablepharma is now better equipped to advance its mission of developing innovative fridge-free vaccines. This collaboration underscores the critical role of strategic financial support in fostering innovation within the biopharmaceutical sector. It also highlights how expert guidance can unlock essential funding, driving impactful research and development. The success of this partnership not only enhances Stablepharma’s financial stability but also reinforces its commitment to revolutionising vaccine accessibility and improving global health outcomes.
Stablepharma Contact Information
Email: info@stablepharma.com
More information can be found on the Company website: https://stablepharma.com/